Targeting HLA class I expression to increase tumor immunogenicity

Tissue Antigens

Volumn 79, Issue 3, 2012, Pages 147-154

  del Campo, A B ^a   Carretero, J ^a,b   Aptsiauri, N ^a   Garrido, F ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Cancer; Gene therapy; Human leukocyte antigen class I; Immune escape

Indexed keywords

HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; IMMUNOGENICITY; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR ESCAPE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84856609577     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01831.x     Document Type: Review

References (53)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004: 10: 909-91.
2. Durrant LG, Spendlove I. Cancer vaccines entering phase III clinical trials. Expert Opin Emerg Drugs 2003: 8: 489-500.
3. Marincola FM, Jafee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000: 74: 181-273.
4. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005: 5: 263-74.
5. Drake CG, Jaffee E, Pardoll DM. Mechanism of immune evasion by tumors. Adv Immunol 2006: 90: 51-81.
6. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997: 18: 89-95.
7. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007: 256: 139-89.
8. Cabrera T, Lara E, Romero JM et al. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007: 56: 709-17.
9. Carretero R, Romero JM, Ruiz-Cabello F et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008: 60: 439-47.
10. Carretero R, Cabrera T, Gil H et al. Garrido F. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer 2011: 129: 839-46.
11. Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 2008: 57: 1727-33.
12. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996: 183: 725-9.
13. Boon T, Coulie PG, Van der Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2005: 24: 631-4.
14. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001: 50: 3-15.
15. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991: 254: 1643-7.
16. Parmiani G, Rivoltini L, Andreola G, Carrabba M. Cytokines in cancer therapy. Immunol Lett 2000: 74: 41-4.
17. Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004: 113: 1515-25.
18. Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006: 13: 905-18.
19. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008: 115: 33-42.
20. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 2000: 20: 2665-76.
21. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006: 24: 175-208.
22. Kruit WH, van Ojik HH, Brichard VG et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005: 117: 596-604.
23. Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005: 175: 6169-76.
24. Anichini A, Vegetti C, Mortarini R. The paradox of T-cell mediated anti-tumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 2004: 53: 855-64.
25. Wang E, Phan GQ, Marincola FM. T-cell-directed cancer vaccines: the melanoma model. Expert Opin Biol Ther 2001: 1: 277-90.
26. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011: 331: 1565-70.
27. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002: 12: 3-13.
28. Marincola F, Jaffee ME, Hicklin D, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000: 74: 181-273.
29. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007: 601: 123-31.
30. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 2001: 91: 109-19.
31. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010: 127: 249-56.
32. Paschen A, Arens N, Sucker A et al. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res 2006: 12: 3297-305.
33. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. Beta2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998: 101: 2720-9.
34. Maleno I, Aptsiauri N, Cabrera T et al. Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics 2011: 63: 65-71.
35. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008: 57: 1719-26.
36. Paschen A, Méndez RM, Jimenez P et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003: 103: 759-67.
37. Kloor M, Michel S, Buckowitz B et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 2007: 121: 454-8.
38. Cabrera CM, Jiménez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003: 61: 211-9.
39. Bicknell D, Rowan CA, Bodmer WF. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumor. Proc Natl Acad Sci U S A 1994: 91: 4751-5.
40. Hsieh CH, Hsu YJ, Chang CC et al. Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes. Cancer Immunol Immunother 2009: 58: 395-408.
41. Nouri AME, Hussain RF, Dos Santos AVL, Gillot DJ, Oliver RTD. Induction of MHC antigens by tumour cell lines in response to interferons. Eur J Cancer 1992: 28: 1110-5.
42. Perez B, Benitez R, Fernandez MA et al. A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 1999: 53: 569-72.
43. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot beta2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen.processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005: 174: 1462-71.
44. Benitez R, Godelaine D, Lopez-Nevot MA et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998: 52: 520-9.
45. McEvoy CR, Seshadri R, Morley AA, Firgaira FA. Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer. Tissue Antigens 2002: 60: 235-43.
46. Chen HL, Gabrilovich D, Virmani A et al. Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer 1996: 67: 756-63.
47. Baba T, Hanagiri T, Takenoyama M et al. Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression. Cancer Sci 2010: 101: 2115-20.
48. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000: 191: 961-76.
49. Malmström PU, Loskog AS, Lindqvist CA et al. AdCD40L immunogene therapy for bladder carcinoma-the first phase I/IIa trial. Clin Cancer Res 2010: 16: 3279-87.
50. Tanaka K, Isselbacher KJ, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985: 228: 26-30.
51. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumor cells by the de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985: 315: 301-5.
52. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 1984: 311: 750-2.
53. del Campo AB, Aptsiauri N, Méndez R et al. Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy. Scand J Immuno 2009: 70: 125-35.